High Prevalence of Cervical High-Risk Human Papillomavirus Harboring Atypical Genotypes in Human Immunodeficiency Virus -Infected and -Uninfected First-Generation Adult Immigrant Women Originating from Sub-Saharan Africa and Living in France

Overview

Journal J Immigr Minor Health

Publisher Springer

Specialties Public Health
Social Sciences

Date 2020 Aug 21

PMID 32816173

Authors

Ralph-Sydney Mboumba Bouassa

Camelia Gubavu

David Veyer

Leman Robin

Anne Gravier

Laurent Hocqueloux

Thierry Prazuck

Helene Pere

Laurent Belec

Affiliations

Soon will be listed here.

Abstract

Human papillomavirus (HPV)-related cervical lesions in first-generation immigrant African women in France should reflect the epidemiology of high-risk (HR)-human papillomavirus (HPV) infection in sub-Saharan Africa. First-generation immigrant African women attending the Centre Hospitalier Régional of Orléans, France, were prospectively subjected to endocervical swabs for HPV DNA PCR and Pap smear. Fifty women (mean age, 41.7 years) living in France (mean stay, 10.7 years) were enrolled, including 26.0% of HIV-negative women from general population and 74.0% of women with known HIV infection. Cervical HPV prevalence was 68.0%, with 56.0% of HR-HPV. HR-HPV -68 and -58 were the predominant genotypes (20.0% and 14.0%, respectively). HR-HPV-16 and HR-HPV-18 were infrequently detected. HIV-infected women showed a trend to be more frequently infected by HPV than HIV-negative women (70.3% versus 61.5%). Most women (84.0%) showed normal cytology, while the remaining (16.0%) exhibited cervical abnormalities and were frequently HIV-infected (87.5%). These observations highlight the unsuspected high burden of cervical HR-HPV infections mostly associated with atypical genotypes, HIV infection and cervical abnormalities in first-generation immigrant African women living in France.

References

Akarolo-Anthony S, Famooto A, Dareng E, Olaniyan O, Offiong R, Wheeler C . Age-specific prevalence of human papilloma virus infection among Nigerian women. BMC Public Health. 2014; 14:656. PMC: 4094683. DOI: 10.1186/1471-2458-14-656. View

Einstein M, Levin M, Chatterjee A, Chakhtoura N, Takacs P, Catteau G . Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study. Hum Vaccin Immunother. 2014; 10(12):3455-65. PMC: 4514093. DOI: 10.4161/hv.36117. View

Paba P, Morosetti G, Criscuolo A, Chiusuri V, Marcuccilli F, Sesti F . Prevalence of human papillomavirus infection in Italian and immigrant women. Int J Immunopathol Pharmacol. 2013; 25(4):1055-62. DOI: 10.1177/039463201202500422. View

Vermund S, Leigh-Brown A . The HIV Epidemic: High-Income Countries. Cold Spring Harb Perspect Med. 2012; 2(5):a007195. PMC: 3331688. DOI: 10.1101/cshperspect.a007195. View

. Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec. 2009; 84(15):118-31. View

Clavel C, Masure M, Bory J, Putaud I, Mangeonjean C, Lorenzato M . Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer. 2001; 84(12):1616-23. PMC: 2363679. DOI: 10.1054/bjoc.2001.1845. View

Faust H, Toft L, Sehr P, Muller M, Bonde J, Forslund O . Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Vaccine. 2016; 34(13):1559-1565. DOI: 10.1016/j.vaccine.2016.02.019. View

Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch F, de Sanjose S . Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010; 202(12):1789-99. DOI: 10.1086/657321. View

Skinner S, Szarewski A, Romanowski B, Garland S, Lazcano-Ponce E, Salmeron J . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014; 384(9961):2213-27. DOI: 10.1016/S0140-6736(14)60920-X. View

10.

Haguenoer K, Sengchanh S, Gaudy-Graffin C, Boyard J, Fontenay R, Marret H . Vaginal self-sampling is a cost-effective way to increase participation in a cervical cancer screening programme: a randomised trial. Br J Cancer. 2014; 111(11):2187-96. PMC: 4260034. DOI: 10.1038/bjc.2014.510. View

11.

McCloskey J, Kast W, Flexman J, McCallum D, French M, Phillips M . Syndemic synergy of HPV and other sexually transmitted pathogens in the development of high-grade anal squamous intraepithelial lesions. Papillomavirus Res. 2017; 4:90-98. PMC: 5883243. DOI: 10.1016/j.pvr.2017.10.004. View

12.

Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K . End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011; 105(1):28-37. PMC: 3137403. DOI: 10.1038/bjc.2011.185. View

13.

Pannetier J, Ravalihasy A, Lydie N, Lert F, du Lou A . Prevalence and circumstances of forced sex and post-migration HIV acquisition in sub-Saharan African migrant women in France: an analysis of the ANRS-PARCOURS retrospective population-based study. Lancet Public Health. 2018; 3(1):e16-e23. DOI: 10.1016/S2468-2667(17)30211-6. View

14.

Kelly H, Sawadogo B, Chikandiwa A, Segondy M, Gilham C, Lompo O . Epidemiology of high-risk human papillomavirus and cervical lesions in African women living with HIV/AIDS: effect of anti-retroviral therapy. AIDS. 2016; 31(2):273-285. DOI: 10.1097/QAD.0000000000001301. View

15.

Stern P, Roden R . Opportunities to improve immune-based prevention of HPV-associated cancers. Papillomavirus Res. 2019; 7:150-153. PMC: 6468155. DOI: 10.1016/j.pvr.2019.04.010. View

16.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

17.

Scheurer M, Tortolero-Luna G, Adler-Storthz K . Human papillomavirus infection: biology, epidemiology, and prevention. Int J Gynecol Cancer. 2005; 15(5):727-46. DOI: 10.1111/j.1525-1438.2005.00246.x. View

18.

Harper D, DeMars L . HPV vaccines - A review of the first decade. Gynecol Oncol. 2017; 146(1):196-204. DOI: 10.1016/j.ygyno.2017.04.004. View

19.

Tornesello M, Rossi P, Buonaguro L, Buonaguro F . Human Papillomavirus Infection and Cervical Neoplasia among Migrant Women Living in Italy. Front Oncol. 2014; 4:31. PMC: 3929937. DOI: 10.3389/fonc.2014.00031. View

20.

Lacey C . HPV vaccination in HIV infection. Papillomavirus Res. 2019; 8:100174. PMC: 6603434. DOI: 10.1016/j.pvr.2019.100174. View